Background: Stroke is largely preventable, and therefore, a better understanding of risk factors is an essential step in reducing the population stroke rate and resulting disease burden in Arab countries. Summary: We performed 2 separate analyses in 2 similar populations of patients with noncardioembolic ischemic stroke. This first involved 3,635 patients in the Outcomes in Patients with TIA and Cerebrovascular disease (OPTIC) registry (followed for 2 years), with baseline collection of the usual risk factors and 5 socioeconomic variables (unemployment status, residence in rural area, living in fully serviced accommodation, no health-insurance coverage, and low educational level). The second involved patients in the PERFORM trial (n = 19,100 followed up for 2 years), with baseline collection of the usual risk factors and 1 socioeconomic variable (low educational level). The primary outcome was a composite of nonfatal stroke, nonfatal myocardial infarction, or cardiovascular death. Stroke risk factors were more prevalent in patients in Arab countries. The incidence of major cardiovascular events (MACE; age- and gender-adjusted) was higher in Arab countries (OPTIC, 18.5 vs. 13.3%; PERFORM, 18.4 vs. 9.7%; both p ≤ 0.0001). These results remained significant after adjustment on risk factors and were attenuated in OPTIC after further adjustment on socioeconomic variables (hazard ratio 1.24; 95% CI 0.98-1.55; p = 0.07). Key Messages: Patients with ischemic stroke living in Arab countries had a lower mean socioeconomic status, a much higher prevalence of diabetes mellitus, and a higher rate of MACE compared with patients from non-Arab countries. This finding is partly explained by a higher prevalence of risk factors and also by a high prevalence of poverty and low educational level.

Keywords:
TIA, Risk factors, Socio-economic status, Stroke
1.
Leys D: Atherothrombosis: a major health burden. Cerebrovasc Dis 2001;11(suppl 2):1-4.
2.
Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-1276.
3.
Murray CJ, Lopez AD, Chin B, Feehan D, Hill KH: Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis. Lancet 2006;368:2211-2218.
4.
Abboud H, Labreuche J, Arauz A, Bryer A, Lavados PG, Massaro A, et al: Demographics, socio-economic characteristics, and risk factor prevalence in patients with non-cardioembolic ischaemic stroke in low- and middle-income countries: the OPTIC registry. Int J Stroke 2013;8(suppl A100):4-13.
5.
Lackland DT, Roccella EJ, Deutsch AF, Fornage M, George MG, Howard G, et al: Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke 2014;45:315-353.
6.
Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V: Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009;8:355-369.
7.
EUROASPIRE II Study Group: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-572.
8.
Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, et al: The prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study: baseline characteristics of the population. Cerebrovasc Dis 2009;27:608-613.
9.
Ghali WA, Quan H, Brant R, van Melle G, Norris CM, Faris PD, et al: Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 2001;286:1494-1497.
10.
Amarenco P, Abboud H, Labreuche J, Arauz A, Bryer A, Lavados PM, et al: Impact of living and socioeconomic characteristics on cardiovascular risk in ischemic stroke patients. Int J Stroke 2014;9:1065-1072.
11.
Tran J, Mirzaei M, Anderson L, Leeder SR: The epidemiology of stroke in the middle East and North Africa. J Neurol Sci 2010;295:38-40.
12.
Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003;289:2363-2369.
13.
Addo J, Smeeth L, Leon DA: Hypertension in sub-saharan Africa: a systematic review. Hypertension 2007;50:1012-1018.
14.
Badran M, Laher I: Type II diabetes mellitus in Arabic-speaking countries. Int J Endocrinol 2012;2012:902873.
15.
Rahim HF, Sibai A, Khader Y, Hwalla N, Fadhil I, Alsiyabi H, et al: Non-communicable diseases in the Arab world. Lancet 2014;383:356-367.
16.
Meyer BF, Alsmadi O, Wakil S, Al-Rubeaanb K: Genetics of type 2 diabetes in Arabs: what we know to date. Int J Diabetes Mellitus 2009;1:32-34.
17.
Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B, et al: Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA 2014;311:183-192.
18.
Maziak W, Ward KD, Afifi Soweid RA, Eissenberg T: Tobacco smoking using a waterpipe: a re-emerging strain in a global epidemic. Tob Control 2004;13:327-333.
19.
Bush J, White M, Kai J, Rankin J, Bhopal R: Understanding influences on smoking in Bangladeshi and Pakistani adults: community based, qualitative study. BMJ 2003;326:962.
20.
Muller-Nordhorn J, Nolte CH, Rossnagel K: Knowledge about risk factors for stroke: a population-based survey of 28,090 participants. Stroke 2006;37:946-950.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.